Prediagnostic levels of C‐peptide, IGF‐I, IGFBP ‐1, ‐2 and ‐3 and risk of endometrial cancer

Conditions related to chronic hyperinsulinemia, such as obesity, noninsulin dependent diabetes mellitus and polycystic ovary syndrome, are associated with an increased risk of endometrial cancer. Elevated plasma IGF‐I and decreased levels of IGF‐binding proteins have been shown to be associated with...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of cancer Vol. 108; no. 2; pp. 262 - 268
Main Authors Lukanova, Annekatrin, Zeleniuch‐Jacquotte, Anne, Lundin, Eva, Micheli, Andrea, Arslan, Alan A., Rinaldi, Sabina, Muti, Paola, Lenner, Per, Koenig, Karen L., Biessy, Carine, Krogh, Vittorio, Riboli, Elio, Shore, Roy E., Stattin, Par, Berrino, Franco, Hallmans, Göran, Toniolo, Paolo, Kaaks, Rudolf
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 10.01.2004
Wiley-Liss
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Conditions related to chronic hyperinsulinemia, such as obesity, noninsulin dependent diabetes mellitus and polycystic ovary syndrome, are associated with an increased risk of endometrial cancer. Elevated plasma IGF‐I and decreased levels of IGF‐binding proteins have been shown to be associated with increased risk of several cancer types that are frequent in affluent societies. We investigated for the first time in a prospective study the association of pre‐diagnostic blood concentrations of C‐peptide (a marker of pancreatic insulin production), IGF‐I, IGFBP‐1, ‐2 and ‐3 with endometrial cancer risk. A case‐control study was nested within 3 cohorts in New York (USA), Umeå (Sweden) and Milan (Italy). It included 166 women with primary invasive endometrial cancer and 315 matched controls, of which 44 case and 78 control subjects were premenopausal at recruitment. Endometrial cancer risk increased with increasing levels of C‐peptide (ptrend = 0.0002), up to an odds ratio (OR) of 4.76 [95% confidence interval (CI) = 1.91–11.8] for the highest quintile. This association remained after adjustment for BMI and other confounders [OR for the top quintile = 4.40 (1.65–11.7)]. IGFBP‐1 levels were inversely related to endometrial cancer [ptrend = 0.002; OR in the upper quintile = 0.30 (0.15–0.62)], but the association was weakened and lost statistical significance after adjustment for confounders [ptrend = 0.06; OR in the upper quintile = 0.49 (0.22–1.07)]. Risk was unrelated to levels of IGF‐I, IGFBP‐2 and IGFBP‐3. Chronic hyperinsulinemia, as reflected by increased circulating C‐peptide, is associated with increased endometrial cancer risk. Decrease in the prevalence of chronic hyperinsulinemia, through changes in lifestyle or medication, is expected to prevent endometrial cancer. © 2003 Wiley‐Liss, Inc.
AbstractList Conditions related to chronic hyperinsulinemia, such as obesity, noninsulin dependent diabetes mellitus and polycystic ovary syndrome, are associated with an increased risk of endometrial cancer. Elevated plasma IGF-I and decreased levels of IGF-binding proteins have been shown to be associated with increased risk of several cancer types that are frequent in affluent societies. We investigated for the first time in a prospective study the association of pre-diagnostic blood concentrations of C-peptide (a marker of pancreatic insulin production), IGF-I, IGFBP-1, -2 and -3 with endometrial cancer risk. A case-control study was nested within 3 cohorts in New York (USA), Umeå (Sweden) and Milan (Italy). It included 166 women with primary invasive endometrial cancer and 315 matched controls, of which 44 case and 78 control subjects were premenopausal at recruitment. Endometrial cancer risk increased with increasing levels of C-peptide ( p trend = 0.0002), up to an odds ratio (OR) of 4.76 [95% confidence interval (CI) = 1.91-11.8] for the highest quintile. This association remained after adjustment for BMI and other confounders [OR for the top quintile = 4.40 (1.65-11.7)]. IGFBP-1 levels were inversely related to endometrial cancer [ p trend = 0.002; OR in the upper quintile = 0.30 (0.15-0.62)], but the association was weakened and lost statistical significance after adjustment for confounders [ p trend = 0.06; OR in the upper quintile = 0.49 (0.22-1.07)]. Risk was unrelated to levels of IGF-I, IGFBP-2 and IGFBP-3. Chronic hyperinsulinemia, as reflected by increased circulating C-peptide, is associated with increased endometrial cancer risk. Decrease in the prevalence of chronic hyperinsulinemia, through changes in lifestyle or medication, is expected to prevent endometrial cancer.
Conditions related to chronic hyperinsulinemia, such as obesity, noninsulin dependent diabetes mellitus and polycystic ovary syndrome, are associated with an increased risk of endometrial cancer. Elevated plasma IGF‐I and decreased levels of IGF‐binding proteins have been shown to be associated with increased risk of several cancer types that are frequent in affluent societies. We investigated for the first time in a prospective study the association of pre‐diagnostic blood concentrations of C‐peptide (a marker of pancreatic insulin production), IGF‐I, IGFBP‐1, ‐2 and ‐3 with endometrial cancer risk. A case‐control study was nested within 3 cohorts in New York (USA), Umeå (Sweden) and Milan (Italy). It included 166 women with primary invasive endometrial cancer and 315 matched controls, of which 44 case and 78 control subjects were premenopausal at recruitment. Endometrial cancer risk increased with increasing levels of C‐peptide (ptrend = 0.0002), up to an odds ratio (OR) of 4.76 [95% confidence interval (CI) = 1.91–11.8] for the highest quintile. This association remained after adjustment for BMI and other confounders [OR for the top quintile = 4.40 (1.65–11.7)]. IGFBP‐1 levels were inversely related to endometrial cancer [ptrend = 0.002; OR in the upper quintile = 0.30 (0.15–0.62)], but the association was weakened and lost statistical significance after adjustment for confounders [ptrend = 0.06; OR in the upper quintile = 0.49 (0.22–1.07)]. Risk was unrelated to levels of IGF‐I, IGFBP‐2 and IGFBP‐3. Chronic hyperinsulinemia, as reflected by increased circulating C‐peptide, is associated with increased endometrial cancer risk. Decrease in the prevalence of chronic hyperinsulinemia, through changes in lifestyle or medication, is expected to prevent endometrial cancer. © 2003 Wiley‐Liss, Inc.
Conditions related to chronic hyperinsulinemia, such as obesity, noninsulin dependent diabetes mellitus and polycystic ovary syndrome, are associated with an increased risk of endometrial cancer. Elevated plasma IGF-I and decreased levels of IGF-binding proteins have been shown to be associated with increased risk of several cancer types that are frequent in affluent societies. We investigated for the first time in a prospective study the association of pre-diagnostic blood concentrations of C-peptide (a marker of pancreatic insulin production), IGF-I, IGFBP-1, -2 and -3 with endometrial cancer risk. A case-control study was nested within 3 cohorts in New York (USA), Umeå (Sweden) and Milan (Italy). It included 166 women with primary invasive endometrial cancer and 315 matched controls, of which 44 case and 78 control subjects were premenopausal at recruitment. Endometrial cancer risk increased with increasing levels of C-peptide (ptrend = 0.0002), up to an odds ratio (OR) of 4.76 [95% confidence interval (CI) = 1.91-11.8] for the highest quintile. This association remained after adjustment for BMI and other confounders [OR for the top quintile = 4.40 (1.65-11.7)]. IGFBP-1 levels were inversely related to endometrial cancer [ptrend = 0.002; OR in the upper quintile = 0.30 (0.15-0.62)], but the association was weakened and lost statistical significance after adjustment for confounders [ptrend = 0.06; OR in the upper quintile = 0.49 (0.22-1.07)]. Risk was unrelated to levels of IGF-I, IGFBP-2 and IGFBP-3. Chronic hyperinsulinemia, as reflected by increased circulating C-peptide, is associated with increased endometrial cancer risk. Decrease in the prevalence of chronic hyperinsulinemia, through changes in lifestyle or medication, is expected to prevent endometrial cancer.
Conditions related to chronic hyperinsulinemia, such as obesity, noninsulin dependent diabetes mellitus and polycystic ovary syndrome, are associated with an increased risk of endometrial cancer. Elevated plasma IGF-I and decreased levels of IGF-binding proteins have been shown to be associated with increased risk of several cancer types that are frequent in affluent societies. We investigated for the first time in a prospective study the association of pre-diagnostic blood concentrations of C-peptide (a marker of pancreatic insulin production), IGF-I, IGFBP-1, -2 and -3 with endometrial cancer risk. A case-control study was nested within 3 cohorts in New York (USA), Umeå (Sweden) and Milan (Italy). It included 166 women with primary invasive endometrial cancer and 315 matched controls, of which 44 case and 78 control subjects were premenopausal at recruitment. Endometrial cancer risk increased with increasing levels of C-peptide (ptrend = 0.0002), up to an odds ratio (OR) of 4.76 [95% confidence interval (CI) = 1.91-11.8] for the highest quintile. This association remained after adjustment for BMI and other confounders [OR for the top quintile = 4.40 (1.65-11.7)]. IGFBP-1 levels were inversely related to endometrial cancer [ptrend = 0.002; OR in the upper quintile = 0.30 (0.15-0.62)], but the association was weakened and lost statistical significance after adjustment for confounders [ptrend = 0.06; OR in the upper quintile = 0.49 (0.22-1.07)]. Risk was unrelated to levels of IGF-I, IGFBP-2 and IGFBP-3. Chronic hyperinsulinemia, as reflected by increased circulating C-peptide, is associated with increased endometrial cancer risk. Decrease in the prevalence of chronic hyperinsulinemia, through changes in lifestyle or medication, is expected to prevent endometrial cancer.Conditions related to chronic hyperinsulinemia, such as obesity, noninsulin dependent diabetes mellitus and polycystic ovary syndrome, are associated with an increased risk of endometrial cancer. Elevated plasma IGF-I and decreased levels of IGF-binding proteins have been shown to be associated with increased risk of several cancer types that are frequent in affluent societies. We investigated for the first time in a prospective study the association of pre-diagnostic blood concentrations of C-peptide (a marker of pancreatic insulin production), IGF-I, IGFBP-1, -2 and -3 with endometrial cancer risk. A case-control study was nested within 3 cohorts in New York (USA), Umeå (Sweden) and Milan (Italy). It included 166 women with primary invasive endometrial cancer and 315 matched controls, of which 44 case and 78 control subjects were premenopausal at recruitment. Endometrial cancer risk increased with increasing levels of C-peptide (ptrend = 0.0002), up to an odds ratio (OR) of 4.76 [95% confidence interval (CI) = 1.91-11.8] for the highest quintile. This association remained after adjustment for BMI and other confounders [OR for the top quintile = 4.40 (1.65-11.7)]. IGFBP-1 levels were inversely related to endometrial cancer [ptrend = 0.002; OR in the upper quintile = 0.30 (0.15-0.62)], but the association was weakened and lost statistical significance after adjustment for confounders [ptrend = 0.06; OR in the upper quintile = 0.49 (0.22-1.07)]. Risk was unrelated to levels of IGF-I, IGFBP-2 and IGFBP-3. Chronic hyperinsulinemia, as reflected by increased circulating C-peptide, is associated with increased endometrial cancer risk. Decrease in the prevalence of chronic hyperinsulinemia, through changes in lifestyle or medication, is expected to prevent endometrial cancer.
Conditions related to chronic hyperinsulinemia, such as obesity, noninsulin dependent diabetes mellitus and polycystic ovary syndrome, are associated with an increased risk of endometrial cancer. Elevated plasma IGF‐I and decreased levels of IGF‐binding proteins have been shown to be associated with increased risk of several cancer types that are frequent in affluent societies. We investigated for the first time in a prospective study the association of pre‐diagnostic blood concentrations of C‐peptide (a marker of pancreatic insulin production), IGF‐I, IGFBP‐1, ‐2 and ‐3 with endometrial cancer risk. A case‐control study was nested within 3 cohorts in New York (USA), Umeå (Sweden) and Milan (Italy). It included 166 women with primary invasive endometrial cancer and 315 matched controls, of which 44 case and 78 control subjects were premenopausal at recruitment. Endometrial cancer risk increased with increasing levels of C‐peptide ( p trend = 0.0002), up to an odds ratio (OR) of 4.76 [95% confidence interval (CI) = 1.91–11.8] for the highest quintile. This association remained after adjustment for BMI and other confounders [OR for the top quintile = 4.40 (1.65–11.7)]. IGFBP‐1 levels were inversely related to endometrial cancer [ p trend = 0.002; OR in the upper quintile = 0.30 (0.15–0.62)], but the association was weakened and lost statistical significance after adjustment for confounders [ p trend = 0.06; OR in the upper quintile = 0.49 (0.22–1.07)]. Risk was unrelated to levels of IGF‐I, IGFBP‐2 and IGFBP‐3. Chronic hyperinsulinemia, as reflected by increased circulating C‐peptide, is associated with increased endometrial cancer risk. Decrease in the prevalence of chronic hyperinsulinemia, through changes in lifestyle or medication, is expected to prevent endometrial cancer. © 2003 Wiley‐Liss, Inc.
Author Lenner, Per
Lukanova, Annekatrin
Koenig, Karen L.
Toniolo, Paolo
Riboli, Elio
Lundin, Eva
Biessy, Carine
Hallmans, Göran
Zeleniuch‐Jacquotte, Anne
Shore, Roy E.
Berrino, Franco
Micheli, Andrea
Rinaldi, Sabina
Muti, Paola
Arslan, Alan A.
Kaaks, Rudolf
Krogh, Vittorio
Stattin, Par
Author_xml – sequence: 1
  givenname: Annekatrin
  surname: Lukanova
  fullname: Lukanova, Annekatrin
– sequence: 2
  givenname: Anne
  surname: Zeleniuch‐Jacquotte
  fullname: Zeleniuch‐Jacquotte, Anne
– sequence: 3
  givenname: Eva
  surname: Lundin
  fullname: Lundin, Eva
– sequence: 4
  givenname: Andrea
  surname: Micheli
  fullname: Micheli, Andrea
– sequence: 5
  givenname: Alan A.
  surname: Arslan
  fullname: Arslan, Alan A.
– sequence: 6
  givenname: Sabina
  surname: Rinaldi
  fullname: Rinaldi, Sabina
– sequence: 7
  givenname: Paola
  surname: Muti
  fullname: Muti, Paola
– sequence: 8
  givenname: Per
  surname: Lenner
  fullname: Lenner, Per
– sequence: 9
  givenname: Karen L.
  surname: Koenig
  fullname: Koenig, Karen L.
– sequence: 10
  givenname: Carine
  surname: Biessy
  fullname: Biessy, Carine
– sequence: 11
  givenname: Vittorio
  surname: Krogh
  fullname: Krogh, Vittorio
– sequence: 12
  givenname: Elio
  surname: Riboli
  fullname: Riboli, Elio
– sequence: 13
  givenname: Roy E.
  surname: Shore
  fullname: Shore, Roy E.
– sequence: 14
  givenname: Par
  surname: Stattin
  fullname: Stattin, Par
– sequence: 15
  givenname: Franco
  surname: Berrino
  fullname: Berrino, Franco
– sequence: 16
  givenname: Göran
  surname: Hallmans
  fullname: Hallmans, Göran
– sequence: 17
  givenname: Paolo
  surname: Toniolo
  fullname: Toniolo, Paolo
– sequence: 18
  givenname: Rudolf
  surname: Kaaks
  fullname: Kaaks, Rudolf
  email: kaaks@iarc.fr
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15441687$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/14639613$$D View this record in MEDLINE/PubMed
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-15439$$DView record from Swedish Publication Index
BookMark eNp1kc1u1DAUhS1URKcDC14AZQNSpUlrx44zWZaBlkGV6ALYWjf2TeXixKmdUHXXR-AZeRI8PxQJwcY-lr9zpHvPETnofY-EvGT0hFFanNobfcJYKcQTMmO0rnJasPKAzNIfzSvG5SE5ivGG0gRR8YwcMiF5LRmfkfYqoLFw3fs4Wp05_I4uZr7NVj8ffgw4jNbgIltfnKfneiveXmVJs8XmLDLozUbwrQg2ftt4sTe-wzFYcJmGXmN4Tp624CK-2N9z8uX8_efVh_zy08V6dXaZa0GFyMtyKRFaLQpZlBKMqRrDmqYQmtZooFlSbSppOAfKC97KGkowknKUBQPgSz4ni11uvMNhatQQbAfhXnmw6p39eqZ8uFZTN6m0LV4n_M0OH4K_nTCOqrNRo3PQo5-iqlhZUZoWNSev9uDUdGgec38vMgGv9wBEDa4NaWwb_3CpHCaXVeJOd5wOPsaArdJ2hNH6fgxgnWJUbSpVqVK1rTQ5jv9yPIb-g92n31mH9_8H1frjauf4BSYVsRY
CODEN IJCNAW
CitedBy_id crossref_primary_10_1016_j_ijrobp_2016_02_048
crossref_primary_10_1016_j_ecl_2012_04_014
crossref_primary_10_1158_1055_9965_EPI_15_1145
crossref_primary_10_1038_nrc1387
crossref_primary_10_1016_j_ajog_2011_05_042
crossref_primary_10_1007_s00223_020_00780_6
crossref_primary_10_1186_1471_2407_14_728
crossref_primary_10_1080_13813450902878054
crossref_primary_10_1158_1055_9965_EPI_06_1062
crossref_primary_10_1152_physrev_00030_2014
crossref_primary_10_1093_aje_kws309
crossref_primary_10_1038_s41598_024_73429_1
crossref_primary_10_1093_aje_kwq006
crossref_primary_10_1002_ijc_22676
crossref_primary_10_1016_j_ygyno_2012_03_012
crossref_primary_10_1158_1055_9965_EPI_06_0775
crossref_primary_10_1038_s41598_017_04526_7
crossref_primary_10_1002_ijc_21354
crossref_primary_10_1093_ajcn_nqac229
crossref_primary_10_1158_1055_9965_EPI_14_0157
crossref_primary_10_3945_ajcn_112_039537
crossref_primary_10_1210_jc_2012_1490
crossref_primary_10_3390_jcm14030751
crossref_primary_10_1038_nrc1408
crossref_primary_10_1080_13813450801954303
crossref_primary_10_1016_j_ygyno_2020_05_033
crossref_primary_10_1158_1055_9965_EPI_11_0766
crossref_primary_10_1002_ijc_27622
crossref_primary_10_1111_jog_14155
crossref_primary_10_1007_s12020_013_9973_3
crossref_primary_10_1158_1055_9965_EPI_10_0832
crossref_primary_10_1007_s00125_007_0681_5
crossref_primary_10_3109_09513590_2012_752452
crossref_primary_10_1016_j_ygyno_2012_03_032
crossref_primary_10_1158_0008_5472_CAN_07_0373
crossref_primary_10_1111_j_1368_504X_2004_00328_x
crossref_primary_10_1002_ijc_22578
crossref_primary_10_1007_s12094_015_1309_8
crossref_primary_10_1158_1055_9965_EPI_11_1105
crossref_primary_10_1080_01635581_2018_1460681
crossref_primary_10_1007_s12672_010_0013_y
crossref_primary_10_1017_S0029665108006976
crossref_primary_10_1007_s10552_013_0314_x
crossref_primary_10_1158_1055_9965_EPI_07_2686
crossref_primary_10_1158_1055_9965_EPI_07_2567
crossref_primary_10_1002_ijc_24927
crossref_primary_10_1158_1055_9965_EPI_06_0960
crossref_primary_10_1210_jc_2006_1371
crossref_primary_10_1007_s43032_020_00423_z
crossref_primary_10_1007_s00125_020_05228_y
crossref_primary_10_1200_JCO_2012_48_2596
crossref_primary_10_12688_wellcomeopenres_16417_1
crossref_primary_10_1007_s13668_014_0112_4
crossref_primary_10_1079_PHN2005741
crossref_primary_10_1016_j_cgh_2006_06_022
crossref_primary_10_1007_s10552_006_0094_7
crossref_primary_10_1158_1078_0432_CCR_16_3011
crossref_primary_10_1007_s00005_011_0119_0
crossref_primary_10_1136_bmjopen_2015_008541
crossref_primary_10_1007_s10552_012_9971_4
crossref_primary_10_1016_j_dsx_2009_08_002
crossref_primary_10_1038_bjc_2012_19
crossref_primary_10_18632_oncotarget_28513
crossref_primary_10_3389_fcell_2022_800181
crossref_primary_10_1158_1055_9965_607_13_4
crossref_primary_10_1007_s00432_022_04288_4
crossref_primary_10_1158_1940_6207_CAPR_16_0224
crossref_primary_10_1080_13813450801969715
crossref_primary_10_1016_j_canlet_2011_11_011
crossref_primary_10_1007_s00432_004_0587_2
crossref_primary_10_1080_13813450801954451
crossref_primary_10_1530_ERC_12_0229
crossref_primary_10_3390_cancers12092559
crossref_primary_10_1002_ijc_28589
crossref_primary_10_1007_s10552_016_0751_4
crossref_primary_10_1038_sj_bjc_6604496
crossref_primary_10_1080_01635580701328073
crossref_primary_10_1038_sj_bjc_6603200
crossref_primary_10_1200_JCO_2010_27_9935
crossref_primary_10_1016_j_ejca_2015_08_031
crossref_primary_10_1111_cas_16447
crossref_primary_10_1586_17474108_1_1_81
crossref_primary_10_3892_ol_2018_9409
crossref_primary_10_1016_j_ygyno_2007_08_002
crossref_primary_10_1158_1055_9965_EPI_06_0465
crossref_primary_10_1590_S0004_27302009000200013
crossref_primary_10_1158_1055_9965_98_14_1
crossref_primary_10_1038_bjc_2013_61
crossref_primary_10_1007_s10620_015_3873_8
crossref_primary_10_1038_s41416_021_01518_3
crossref_primary_10_1158_1055_9965_EPI_06_0625
crossref_primary_10_1016_j_soard_2017_01_042
crossref_primary_10_1080_00016340802160079
crossref_primary_10_1155_2013_632461
crossref_primary_10_3390_cancers13092149
crossref_primary_10_3892_ijo_2015_2865
crossref_primary_10_1016_j_heliyon_2023_e16470
crossref_primary_10_1007_s10911_008_9104_6
crossref_primary_10_1016_j_beem_2008_08_003
crossref_primary_10_1080_09513590400021201
crossref_primary_10_1158_1055_9965_EPI_20_0965
crossref_primary_10_1371_journal_pone_0129824
crossref_primary_10_1002_cncr_28853
crossref_primary_10_1158_1055_9965_195_14_1
crossref_primary_10_1158_1055_9965_EPI_06_0751
crossref_primary_10_1016_j_ejogrb_2016_06_013
crossref_primary_10_1042_CS20090399
crossref_primary_10_1016_j_ygyno_2016_01_020
crossref_primary_10_1002_ijc_23900
crossref_primary_10_3390_nu12010114
crossref_primary_10_1002_ijc_22140
crossref_primary_10_1007_s12328_010_0177_6
crossref_primary_10_1016_j_soard_2014_08_012
crossref_primary_10_1186_s12885_017_3068_0
crossref_primary_10_1158_0008_5472_CAN_20_1281
crossref_primary_10_3389_fnut_2023_1291355
crossref_primary_10_3390_cancers17010129
crossref_primary_10_1093_aje_kwm161
crossref_primary_10_1007_s00394_012_0376_7
crossref_primary_10_1586_17446651_2016_1128325
crossref_primary_10_1016_j_semcancer_2024_01_003
crossref_primary_10_1002_ijc_22422
crossref_primary_10_1093_annonc_mdv142
crossref_primary_10_1002_ijc_24722
crossref_primary_10_1016_j_ygyno_2009_12_029
Cites_doi 10.1136/gut.50.5.642
10.1023/A:1022518321634
10.1016/S0002-9378(98)70244-3
10.1002/sim.935
10.1159/000299079
10.1210/jc.76.5.1115
10.1097/00001648-200011000-00004
10.1210/edrv.21.3.0399
10.1002/ijc.2910590303
10.2307/2347069
10.1080/1464727002000198781
10.1002/(SICI)1097-0215(19970502)71:3<360::AID-IJC9>3.0.CO;2-W
10.3109/09513599809012842
10.1210/jc.75.5.1235
10.1006/gyno.1993.1134
10.1016/0378-5122(95)00935-E
10.1093/jnci/92.19.1592
10.1038/bjc.1988.44
10.1093/oxfordjournals.aje.a009065
10.1210/edrv-11-3-443
10.1111/j.1749-6632.1991.tb37856.x
10.1210/jcem-67-1-144
10.1016/S0083-6729(08)60444-6
10.1002/1097-0142(194911)2:6<957::AID-CNCR2820020604>3.0.CO;2-6
10.1210/er.16.1.3
10.1079/PNS200070
10.1006/gyno.1998.5089
10.1210/jc.77.1.199
10.1023/A:1016392129279
10.1002/1097-0215(200002)9999:9999<::AID-IJC1053>3.0.CO;2-T
10.1093/oxfordjournals.aje.a009301
10.1023/A:1013708627664
10.1002/1097-0215(20001201)88:5<828::AID-IJC22>3.0.CO;2-8
ContentType Journal Article
Copyright Copyright © 2003 Wiley‐Liss, Inc.
2004 INIST-CNRS
Copyright 2003 Wiley-Liss, Inc.
Copyright_xml – notice: Copyright © 2003 Wiley‐Liss, Inc.
– notice: 2004 INIST-CNRS
– notice: Copyright 2003 Wiley-Liss, Inc.
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ADTPV
AOWAS
D93
DOI 10.1002/ijc.11544
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
SwePub
SwePub Articles
SWEPUB Umeå universitet
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

MEDLINE
MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1097-0215
EndPage 268
ExternalDocumentID oai_DiVA_org_umu_15439
14639613
15441687
10_1002_ijc_11544
IJC11544
Genre article
Multicenter Study
Research Support, U.S. Gov't, P.H.S
Comparative Study
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Italy
Sweden
United States
North America
Europe
America
GrantInformation_xml – fundername: US National Cancer Institute
  funderid: R01 CA81188‐01; R01 CA81200‐01; R01 CA81212‐01; R01 CA34588
– fundername: NCI NIH HHS
  grantid: R01 CA81188-01
– fundername: NCI NIH HHS
  grantid: R01 CA81200-01
– fundername: NCI NIH HHS
  grantid: R01 CA34588
– fundername: NCI NIH HHS
  grantid: R01 CA81212-01
GroupedDBID ---
-~X
.3N
.55
.GA
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
24P
31~
33P
3O-
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABIJN
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EJD
EX3
F00
F01
F04
F5P
FUBAC
G-S
G.N
GNP
GODZA
H.X
HBH
HGLYW
HHY
HHZ
HZ~
IH2
IX1
J0M
JPC
KBYEO
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OK1
P2P
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RIWAO
RJQFR
ROL
RWI
RX1
SUPJJ
UB1
UDS
V2E
V8K
V9Y
W2D
W8V
W99
WBKPD
WHWMO
WIB
WIH
WIJ
WIK
WIN
WJL
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WWO
WXI
WXSBR
X7M
XG1
XPP
XV2
ZZTAW
~IA
~WT
AAYXX
AEYWJ
AGYGG
CITATION
.GJ
8WZ
A6W
AAMMB
AANHP
ABEFU
ABEML
ACBWZ
ACRPL
ACSCC
ACYXJ
ADNMO
AEFGJ
AGHNM
AGQPQ
AGXDD
AHEFC
AI.
AIDQK
AIDYY
ASPBG
AVWKF
AZFZN
BDRZF
C45
EMOBN
FEDTE
GLUZI
HF~
HVGLF
IQODW
M6P
OVD
PALCI
RYL
SAMSI
TEORI
VH1
Y6R
ZGI
ZXP
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ADTPV
AOWAS
D93
ID FETCH-LOGICAL-c4044-5586eafc426256add7bd1bb24c09edab80cd76d33a0323f69a5ad603e621aa383
IEDL.DBID DR2
ISSN 0020-7136
1097-0215
IngestDate Thu Aug 21 06:40:39 EDT 2025
Fri Jul 11 16:33:08 EDT 2025
Wed Feb 19 01:51:43 EST 2025
Mon Jul 21 09:12:04 EDT 2025
Tue Jul 01 04:26:19 EDT 2025
Thu Apr 24 23:12:47 EDT 2025
Wed Jan 22 16:39:06 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Human
Endometrium cancer
Peptides
Malignant tumor
Case control study
Insulin like growth factor 1
Epidemiology
C-Peptide
Female genital diseases
Polypeptide
Insulin like growth factor binding protein 1
Cohort study
Risk factor
Uterine diseases
Public health
Growth factor
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
CC BY 4.0
Copyright 2003 Wiley-Liss, Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4044-5586eafc426256add7bd1bb24c09edab80cd76d33a0323f69a5ad603e621aa383
Notes The content of this report is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. The NSHDS is sponsored by the Swedish Cancer Society and the ORDET cohort is sponsored by the Italian Association of Cancer Research.
Fax +33‐4‐72‐73‐86‐31
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.11544
PMID 14639613
PQID 71570061
PQPubID 23479
PageCount 7
ParticipantIDs swepub_primary_oai_DiVA_org_umu_15439
proquest_miscellaneous_71570061
pubmed_primary_14639613
pascalfrancis_primary_15441687
crossref_citationtrail_10_1002_ijc_11544
crossref_primary_10_1002_ijc_11544
wiley_primary_10_1002_ijc_11544_IJC11544
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 10 January 2004
PublicationDateYYYYMMDD 2004-01-10
PublicationDate_xml – month: 01
  year: 2004
  text: 10 January 2004
  day: 10
PublicationDecade 2000
PublicationPlace Hoboken
PublicationPlace_xml – name: Hoboken
– name: New York, NY
– name: United States
PublicationTitle International journal of cancer
PublicationTitleAlternate Int J Cancer
PublicationYear 2004
Publisher Wiley Subscription Services, Inc., A Wiley Company
Wiley-Liss
Publisher_xml – name: Wiley Subscription Services, Inc., A Wiley Company
– name: Wiley-Liss
References 2001; 91
1993; 47
1990; 11
1993; 49
1997; 44
1995; 16
2002; 50
2000; 3
2000; 21
2002; 6
2000; 88
1982; 31
2002; 13
1949; 2
2002; 11
2003; 14
2000; 92
1988; 57
1978; 38
1992; 75
1998; 179
2001; 20
1997; 146
1997; VII
2001; 60
1997; 71
1990
1993; 77
2000; 11
1993; 76
1995; 22
1997; 145
1988; 67
1984; 18
1998; 70
1994; 59
2001; 12
1991; 622
1998; 12
Gamayunova VB (e_1_2_6_12_2) 1997; 44
e_1_2_6_31_2
Kaaks R (e_1_2_6_5_2) 2002; 11
e_1_2_6_18_2
e_1_2_6_19_2
e_1_2_6_35_2
e_1_2_6_13_2
e_1_2_6_10_2
e_1_2_6_33_2
e_1_2_6_11_2
e_1_2_6_32_2
e_1_2_6_16_2
e_1_2_6_39_2
e_1_2_6_17_2
e_1_2_6_38_2
Parkin DM (e_1_2_6_2_2) 1997
e_1_2_6_14_2
e_1_2_6_37_2
e_1_2_6_15_2
e_1_2_6_36_2
Holmes MD (e_1_2_6_34_2) 2002; 11
e_1_2_6_20_2
Siiteri PK (e_1_2_6_30_2) 1978; 38
e_1_2_6_41_2
e_1_2_6_40_2
e_1_2_6_8_2
e_1_2_6_7_2
e_1_2_6_9_2
e_1_2_6_29_2
Vainio H (e_1_2_6_3_2) 2002
e_1_2_6_4_2
e_1_2_6_6_2
e_1_2_6_24_2
e_1_2_6_23_2
e_1_2_6_22_2
e_1_2_6_21_2
e_1_2_6_28_2
e_1_2_6_27_2
e_1_2_6_26_2
e_1_2_6_25_2
References_xml – volume: 14
  start-page: 65
  year: 2003
  end-page: 74
  article-title: Lifestyle determinants of serum insulin‐like growth‐factor‐I (IGF‐I), C‐peptide and hormone binding protein levels in British women
  publication-title: Cancer Causes Control
– volume: 75
  start-page: 1235
  year: 1992
  end-page: 41
  article-title: Steroid and peptide regulation of insulin‐like growth factor‐binding proteins secreted by human endometrial stromal cells is dependent on stromal differentiation
  publication-title: J Clin Endocrinol Metab
– volume: 3
  start-page: 101
  year: 2000
  end-page: 105
  article-title: Long‐term consequences of polycystic ovary syndrome: results of a 31 year follow‐up study
  publication-title: Hum Fertil (Camb.)
– volume: 2
  start-page: 957
  year: 1949
  end-page: 63
  article-title: Genesis of endometrial carcinoma. II. Cases 19 to 35 years old
  publication-title: Cancer
– volume: 44
  start-page: 123
  year: 1997
  end-page: 6
  article-title: Comparative study of blood insulin levels in breast and endometrial cancer patients
  publication-title: Neoplasma
– volume: 59
  start-page: 307
  year: 1994
  end-page: 12
  article-title: Suppressed expression of insulin‐like growth factor binding protein‐1 mRNA in the endometrium: a molecular mechanism associating endometrial cancer with its risk factors
  publication-title: Int J Cancer
– volume: 12
  start-page: 399
  year: 1998
  end-page: 406
  article-title: Insulin‐like growth factors in endometrial function
  publication-title: Gynecol Endocrinol
– volume: 6
  year: 2002
– volume: 179
  start-page: 6
  year: 1998
  end-page: 12
  article-title: Specific binding and growth‐promoting activity of insulin in endometrial cancer cells in culture
  publication-title: Am J Obstet Gynecol
– volume: 70
  start-page: 202
  year: 1998
  end-page: 9
  article-title: Transforming growth factor‐alpha and insulin‐like growth factor‐I, but not epidermal growth factor, elicit autocrine stimulation of mitogenesis in endometrial cancer cell lines
  publication-title: Gynecol Oncol
– volume: 11
  start-page: 862
  year: 2002
  end-page: 7
  article-title: Lifestyle correlates of plasma insulin‐like growth factor I and insulin‐like growth factor binding protein 3 concentrations
  publication-title: Cancer Epidemiol Biomarkers Prev
– year: 1990
– volume: 12
  start-page: 951
  year: 2001
  end-page: 8
  article-title: Determinants of circulating insulin‐like growth factor (IGF)‐I and IGF binding proteins 1‐3 in premenopausal women: physical activity and anthropometry (Netherlands)
  publication-title: Cancer Causes Control
– volume: 77
  start-page: 199
  year: 1993
  end-page: 204
  article-title: Relationship between carbohydrate metabolism and serum insulin‐like growth factor system in postmenopausal women: comparison of endometrial cancer patients with healthy controls
  publication-title: J Clin Endocrinol Metab
– volume: 71
  start-page: 360
  year: 1997
  end-page: 3
  article-title: Risk of endometrial and breast cancer in patients with diabetes mellitus
  publication-title: Int J Cancer
– volume: 146
  start-page: 476
  year: 1997
  end-page: 82
  article-title: Insulin and endometrial cancer
  publication-title: Am J Epidemiol
– volume: 60
  start-page: 91
  year: 2001
  end-page: 106
  article-title: Energy balance and cancer: the role of insulin and insulin‐like growth factor‐I
  publication-title: Proc Nutr Soc
– volume: 22
  start-page: 255
  year: 1995
  end-page: 62
  article-title: Insulin‐like growth factor‐binding protein‐1: a biochemical marker of endometrial response to progestin during hormone replacement therapy
  publication-title: Maturitas
– volume: 50
  start-page: 642
  year: 2002
  end-page: 6
  article-title: Plasma IGF‐I, IGF‐binding protein‐3 and risk of colorectal cancer: A prospective study in Northern Sweden
  publication-title: Gut
– volume: 145
  start-page: 970
  year: 1997
  end-page: 6
  article-title: Epidemiology of insulin‐like growth factor‐I in elderly men and women: The Rancho Bernardo Study
  publication-title: Am J Epidemiol
– volume: 16
  start-page: 3
  year: 1995
  end-page: 34
  article-title: Insulin‐like growth factors and their binding proteins: biological actions
  publication-title: Endocr Rev
– volume: 11
  start-page: 443
  year: 1990
  end-page: 53
  article-title: Uterine insulin‐like growth factor‐1: regulation of expression and its role in estrogen‐induced uterine proliferation
  publication-title: Endocr Rev
– volume: 57
  start-page: 205
  year: 1988
  end-page: 12
  article-title: The dose‐effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk
  publication-title: Br J Cancer
– volume: 21
  start-page: 215
  year: 2000
  end-page: 44
  article-title: The effects of insulin‐like growth factors on tumorigenesis and neoplastic growth
  publication-title: Endocr Rev
– volume: 622
  start-page: 120
  year: 1991
  end-page: 37
  article-title: The insulin‐like growth factor binding proteins: the endometrium and decidua
  publication-title: Ann N Y Acad Sci
– volume: 47
  start-page: 1
  year: 1993
  end-page: 114
  article-title: Insulin‐like growth factor binding proteins
  publication-title: Vitam Horm
– volume: 11
  start-page: 635
  year: 2000
  end-page: 40
  article-title: Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha‐hydroxyestrone ratio in premenopausal and postmenopausal women
  publication-title: Epidemiology
– volume: 13
  start-page: 509
  year: 2002
  end-page: 16
  article-title: Nonlinear relationship of insulin‐like growth factor (IGF)‐I and IGF‐I/IGF‐binding protein‐3 ratio with indices of adiposity and plasma insulin concentrations (Sweden)
  publication-title: Cancer Causes Control
– volume: 92
  start-page: 1592
  year: 2000
  end-page: 600
  article-title: Serum C‐Peptide, Insulin‐Like Growth Factor (IGF)‐I, IGF‐Binding Proteins, and Colorectal Cancer Risk in Women
  publication-title: J Natl Cancer Inst
– volume: 18
  start-page: 190
  year: 1984
  end-page: 3
  article-title: Increased rate of glucose intolerance in endometrial cancer: a community‐based study
  publication-title: Gynecol Obstet Invest
– volume: 76
  start-page: 1115
  year: 1993
  end-page: 22
  article-title: Differential expression of messenger ribonucleic acids encoding insulin‐like growth factors and their receptors in human uterine endometrium and decidua
  publication-title: J Clin Endocrinol Metab
– volume: 49
  start-page: 325
  year: 1993
  end-page: 32
  article-title: Mitogenic activity of growth factors in the human endometrial adenocarcinoma cell lines HEC‐1‐A and KLE
  publication-title: Gynecol Oncol
– volume: VII
  year: 1997
– volume: 31
  start-page: 9
  year: 1982
  end-page: 13
  article-title: A generalization of the paired t‐test
  publication-title: Appl Statistics
– volume: 11
  start-page: 1531
  year: 2002
  end-page: 43
  article-title: Obesity, endogenous hormones, and endometrial cancer risk; a synthetic review
  publication-title: Cancer Epidemiol Biomarkers Prev
– volume: 88
  start-page: 828
  year: 2000
  end-page: 32
  article-title: Serum insulin‐like growth factor‐I and breast cancer
  publication-title: Int J Cancer
– volume: 20
  start-page: 3205
  year: 2001
  end-page: 14
  article-title: Planning a reproducibility study: how many subjects and how many replicates per subject for an expected width of the 95 per cent confidence interval of the intraclass correlation coefficient
  publication-title: Stat Med
– volume: 67
  start-page: 144
  year: 1988
  end-page: 8
  article-title: Hyperinsulinemia and stromal luteinization of the ovaries in postmenopausal women with endometrial cancer
  publication-title: J Clin Endocrinol Metab
– volume: 91
  start-page: 421
  year: 2001
  end-page: 30
  article-title: Overweight as an avoidable cause of cancer in Europe
  publication-title: Int J Cancer
– volume: 38
  start-page: 4360
  year: 1978
  end-page: 6
  article-title: Steroid hormones and endometrial cancer
  publication-title: Cancer Res
– ident: e_1_2_6_26_2
  doi: 10.1136/gut.50.5.642
– ident: e_1_2_6_36_2
  doi: 10.1023/A:1022518321634
– ident: e_1_2_6_8_2
  doi: 10.1016/S0002-9378(98)70244-3
– ident: e_1_2_6_29_2
  doi: 10.1002/sim.935
– volume: 44
  start-page: 123
  year: 1997
  ident: e_1_2_6_12_2
  article-title: Comparative study of blood insulin levels in breast and endometrial cancer patients
  publication-title: Neoplasma
– ident: e_1_2_6_13_2
  doi: 10.1159/000299079
– ident: e_1_2_6_37_2
  doi: 10.1210/jc.76.5.1115
– ident: e_1_2_6_25_2
  doi: 10.1097/00001648-200011000-00004
– volume: 11
  start-page: 862
  year: 2002
  ident: e_1_2_6_34_2
  article-title: Lifestyle correlates of plasma insulin‐like growth factor I and insulin‐like growth factor binding protein 3 concentrations
  publication-title: Cancer Epidemiol Biomarkers Prev
– ident: e_1_2_6_15_2
  doi: 10.1210/edrv.21.3.0399
– ident: e_1_2_6_18_2
  doi: 10.1002/ijc.2910590303
– ident: e_1_2_6_27_2
  doi: 10.2307/2347069
– ident: e_1_2_6_7_2
  doi: 10.1080/1464727002000198781
– ident: e_1_2_6_6_2
  doi: 10.1002/(SICI)1097-0215(19970502)71:3<360::AID-IJC9>3.0.CO;2-W
– ident: e_1_2_6_38_2
  doi: 10.3109/09513599809012842
– ident: e_1_2_6_39_2
  doi: 10.1210/jc.75.5.1235
– ident: e_1_2_6_40_2
  doi: 10.1006/gyno.1993.1134
– year: 1997
  ident: e_1_2_6_2_2
– ident: e_1_2_6_22_2
  doi: 10.1016/0378-5122(95)00935-E
– ident: e_1_2_6_32_2
  doi: 10.1093/jnci/92.19.1592
– ident: e_1_2_6_21_2
  doi: 10.1038/bjc.1988.44
– ident: e_1_2_6_31_2
  doi: 10.1093/oxfordjournals.aje.a009065
– volume: 38
  start-page: 4360
  year: 1978
  ident: e_1_2_6_30_2
  article-title: Steroid hormones and endometrial cancer
  publication-title: Cancer Res
– ident: e_1_2_6_17_2
  doi: 10.1210/edrv-11-3-443
– ident: e_1_2_6_20_2
  doi: 10.1111/j.1749-6632.1991.tb37856.x
– ident: e_1_2_6_11_2
  doi: 10.1210/jcem-67-1-144
– ident: e_1_2_6_23_2
  doi: 10.1016/S0083-6729(08)60444-6
– ident: e_1_2_6_41_2
  doi: 10.1002/1097-0142(194911)2:6<957::AID-CNCR2820020604>3.0.CO;2-6
– ident: e_1_2_6_19_2
  doi: 10.1210/er.16.1.3
– ident: e_1_2_6_16_2
  doi: 10.1079/PNS200070
– ident: e_1_2_6_28_2
– ident: e_1_2_6_14_2
  doi: 10.1006/gyno.1998.5089
– volume: 11
  start-page: 1531
  year: 2002
  ident: e_1_2_6_5_2
  article-title: Obesity, endogenous hormones, and endometrial cancer risk; a synthetic review
  publication-title: Cancer Epidemiol Biomarkers Prev
– ident: e_1_2_6_10_2
  doi: 10.1210/jc.77.1.199
– ident: e_1_2_6_33_2
  doi: 10.1023/A:1016392129279
– ident: e_1_2_6_4_2
  doi: 10.1002/1097-0215(200002)9999:9999<::AID-IJC1053>3.0.CO;2-T
– year: 2002
  ident: e_1_2_6_3_2
– ident: e_1_2_6_9_2
  doi: 10.1093/oxfordjournals.aje.a009301
– ident: e_1_2_6_35_2
  doi: 10.1023/A:1013708627664
– ident: e_1_2_6_24_2
  doi: 10.1002/1097-0215(20001201)88:5<828::AID-IJC22>3.0.CO;2-8
SSID ssj0011504
Score 2.1789336
Snippet Conditions related to chronic hyperinsulinemia, such as obesity, noninsulin dependent diabetes mellitus and polycystic ovary syndrome, are associated with an...
SourceID swepub
proquest
pubmed
pascalfrancis
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 262
SubjectTerms Adult
Aged
Biological and medical sciences
Biomarkers, Tumor - blood
C-peptide
C-Peptide - blood
Case-Control Studies
Chronic Disease
Cohort Studies
cohort study
endometrial cancer
Endometrial Neoplasms - blood
Endometrial Neoplasms - diagnosis
Female
Female genital diseases
Gynecology. Andrology. Obstetrics
Humans
Hyperinsulinism - blood
Insulin - metabolism
Insulin-Like Growth Factor Binding Protein 1 - blood
Insulin-Like Growth Factor Binding Protein 2 - blood
Insulin-Like Growth Factor Binding Protein 3 - blood
insulin-like growth factor binding proteins
Insulin-Like Growth Factor I - metabolism
insulin-like growth factor-I
Medical sciences
MEDICIN
MEDICINE
Middle Aged
Prognosis
Prospective Studies
Risk Factors
Tumors
Title Prediagnostic levels of C‐peptide, IGF‐I, IGFBP ‐1, ‐2 and ‐3 and risk of endometrial cancer
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fijc.11544
https://www.ncbi.nlm.nih.gov/pubmed/14639613
https://www.proquest.com/docview/71570061
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-15439
Volume 108
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqHhASAsozQIuFQOLQbJ2Xk4hTu2XpViqqEEU9IFmOH6jQJqvdzYUTP4HfyC9hxk6yWlQkxCWaKGMltmfsz_H4G0JeRorBJFvI0OokDtOy0DAOIm1lDsZkLS8id1zs5D0_OkuPz7PzDfKmPwvj-SGGH27oGW68RgeX1WJvRRp68VWNHJcMjL8Yq4WA6MNAHYVAp2NgZiEsxHjPKsTivaHk2lx0ayYX0CzW57O4DnAObKLrQNbNRJM75HNfBx-A8m3ULquR-v4HveN_VvIuud0hVLrvTWqLbJj6Hrlx0u3B3yf2dI6nTTBADzToJUYdLWhj6fjXj58zDJLRZpdO303gduqEg1MKcrSL15jKWqOQOAEj27GsqXVzZVwKEarQEOcPyNnk7cfxUdhlawhVCv0dZlnBjbQKKe4zDsNmXumoquJUsdJoWRVM6ZzrJJEsiRPLS5lJzVlieBxJCQvlh2SzbmrzmFAkjU-ZtSyRKQAcXVlZIvCKUlkontmAvO77TaiOyhwzalwKT8IcC2g34dotIC8G1Znn77hOaWet81eamKGNF3lAnvfWIMD9cE9F1qZpFyKPMEEAjwLyyBvJqmwK4A_AUkBeeasZniCj9-HFp33RzL-I9qrF1yQlVMpZwt8_U0yPx0548u-qT8lNH2uEgYvPyOZy3pptgFHLasf5y29L_Bh9
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgES4k0JlDZCIHFots7LSaReysKyW7pVhdqqF2Q5flSFNlntbi6c-An9jf0leJzHalGREJdoooyV2J6xPzvjbwDe-oKYSTblnpZh4EVZKs04iLSViTEmrWnq2-Ni4wM6PI72TuPTFdhpz8LU_BDdhht6hh2v0cFxQ3p7wRp6_l30LJnMLbiNGb3tguprRx6FUKfhYCaeWYrRlleIBNtd0aXZ6P6Ez0zD6DqjxU2Qs-MTXYaydi4aPIRvbS3qEJQfvWqe98TPPwge_7eaj-BBA1Ld3dqqHsOKKp7AnXHzG_4p6MMpHjjBGD2j4V5g4NHMLbXbv_51NcE4Gam23NHngbkdWeHDoWtkfwuvgcsLiUJoBQxux7KqkOWlsllEXIG2OH0Gx4NPR_2h1yRs8ERkutyL45QqrgWy3MfUjJxJLv08DyJBMiV5nhIhEyrDkJMwCDXNeMwlJaGigc-5WSs_h9WiLNQLcJE3PiJak5BHBuPIXPMMsZcf8VTQWDvwvu04Jho2c0yqccFqHuaAmXZjtt0ceNOpTmoKj5uUNpZ6f6GJSdpomjiw2ZoDMx6Iv1V4ocpqxhIfcwRQ34G12koWZSOD_wxecuBdbTbdEyT1_nh-ssvK6RmrLit8TZiZSllT-PtnstFe3wov_111E-4Oj8b7bH908OUV3KtDjzCOcR1W59NKvTaoap5vWOf5DbdFHJg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIlVIiPcjPNoIgcSh2TovJxGnssvSLbRaIYp6QLIcP1ChTVa7mwsnfgK_kV-Cx06yWlQkxCWaKGMltmfsz_H4G4DnoSBmks15oGUcBUmRSzMOIm1lZoxJa5qH9rjY0TE9OEkOT9PTDXjVnYVx_BD9Dzf0DDteo4PPpN5bkYaefRUDyyVzBa4mlORo0qMPPXcUIp2WgpkEZiVGO1ohEu31Rdcmo-szvjDtol1Ci8sQZ08nuo5k7VQ0vgmfu0q4CJRvg2ZZDsT3P_gd_7OWt-BGC1H9fWdTt2FDVXdg66jdhL8LejrH4yYYoWc0_HMMO1r4tfaHv378nGGUjFS7_uTt2NxOrPB66hs53MVr5PNKohBbAUPbsayqZH2hbA4RX6Alzu_ByfjNx-FB0KZrCERiOjxI05wqrgVy3KfUjJtZKcOyjBJBCiV5mRMhMyrjmJM4ijUteMolJbGiUci5WSnfh82qrtRD8JE1PiFak5gnBuHIUvMCkVeY8FzQVHvwsus3Jlouc0ypcc4cC3PETLsx224ePOtVZ47A4zKl7bXOX2liijaaZx7sdNbAjP_hpgqvVN0sWBZihgAaevDAGcmqbGLQn0FLHrxwVtM_QUrv0dmnfVbPv7DmosHXxIWplLWEv38mmxwOrfDo31V3YGs6GrP3k-N3j-GaizvCIMYnsLmcN-qpgVTLctu6zm9xeRtQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prediagnostic+levels+of+C-peptide%2C+IGF-I%2C+IGFBP+-1%2C+-2+and+-3+and+risk+of+endometrial+cancer&rft.jtitle=International+journal+of+cancer&rft.au=LUKANOVA%2C+Annekatrin&rft.au=ZELLNIUCH-JACQUOTTE%2C+Anne&rft.au=KROGH%2C+Vittorio&rft.au=RIBOLI%2C+Elio&rft.date=2004-01-10&rft.pub=Wiley-Liss&rft.issn=0020-7136&rft.volume=108&rft.issue=2&rft.spage=262&rft.epage=268&rft_id=info:doi/10.1002%2Fijc.11544&rft.externalDBID=n%2Fa&rft.externalDocID=15441687
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0020-7136&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0020-7136&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0020-7136&client=summon